|
Delayed
London S.E.
07:48:42 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 0.1834 GBX | -0.86% |
|
-3.47% | -8.30% |
| 08-20 | Theracryf's fund raise; Potter & Moore sales struggle | AN |
| 05-14 | EARNINGS & TRADING: Nexus Infrastructure first-half loss narrows | AN |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 5.38M | - | - | - | - | - |
| 69.02B | |||||
| 66.32B | |||||
| 27.66B | - | ||||
| 25.84B | - | ||||
| 26.54B |
- Stock Market
- Stocks
- EVG Stock
- Charts Theracryf Plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
